Related Experiment Video
Updated: Jun 3, 2025
08:43
Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts
Published on: August 26, 2021
2.3K
Sonogenetics is a novel antiarrhythmic mechanism.
Yang Li1,2, Xingang Wang2, Jianzhong Guo2
1School of Science, Beijing University of Posts and Telecommunications, Beijing 100876, China.
Chaos (Woodbury, N.Y.)
|January 10, 2025
Summary
This study introduces a novel sonogenetic therapy for heart arrhythmia, using focused ultrasound to control ion channels and restore normal rhythm. This non-invasive approach offers a safer, more adaptable alternative to implantable cardioverter defibrillators (ICDs).
Area of Science:
- Biomedical Engineering
- Cardiology
- Biophysics
Background:
- Heart arrhythmia poses significant health risks.
- Current treatments like implantable cardioverter defibrillators (ICDs) are invasive and impact patient quality of life.
Purpose of the Study:
- To propose and analyze a novel sonogenetic mechanism for treating cardiac arrhythmia.
- To investigate the potential of focused ultrasound to restore normal heart rhythm non-invasively.
Main Methods:
- Utilizing focused ultrasound to target cardiac tissue and modulate stretch-activated Piezo1 ion channels.
- Developing an interdisciplinary electro-mechanical model to simulate sonogenetic treatment.
- Analyzing ultrasound intensity and frequency parameters for safety and efficacy.
Main Results:
- The proposed sonogenetic mechanism offers dynamic control over the treatment area, unlike fixed ICD leads.
- Simulations indicate that the proposed ultrasound parameters are safe and painless for humans.
- The method presents a novel and potentially more efficient defibrillation strategy.
Conclusions:
- Sonogenetic therapy using focused ultrasound is a promising non-invasive alternative for treating heart arrhythmia.
- This approach enhances treatment adaptability and patient quality of life compared to traditional ICDs.
- Further research and validation of the proposed electro-mechanical model are warranted.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
900
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
900
01:26Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
01:21G-Protein Gated Ion Channels
4.5K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
4.5K